CNC Q4 2025

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025

Earnings

Centene Corporation posted a narrower-than-feared loss in Q4 2025, with adjusted diluted EPS of $-1.19 beating the consensus estimate of $-1.22 by 2.46%, while revenue of $49.73 billion topped expectations of $47.62 billion by 4.42% and grew 21.9% ye… Read more Centene Corporation posted a narrower-than-feared loss in Q4 2025, with adjusted diluted EPS of $-1.19 beating the consensus estimate of $-1.22 by 2.46%, while revenue of $49.73 billion topped expectations of $47.62 billion by 4.42% and grew 21.9% year over year. The headline story, however, remained the weight of non-cash impairment charges, including a $513 million Magellan Health write-down tied to a December divestiture agreement, which contributed to a GAAP diluted loss of $-2.24 per share for the quarter. Beneath those charges, the underlying business showed signs of stabilization; Medicaid's health benefits ratio improved 40 basis points sequentially, and SG&A discipline was evident with the adjusted ratio tightening to 7.5% from 8.9% a year earlier. Deutsche Bank raised its price target on the stock following the results, though it maintained a Hold rating, reflecting cautious optimism about the recovery trajectory. Looking ahead, Centene guided for 2026 total revenues of $186.50 billion to $190.50 billion and adjusted diluted EPS greater than $3.00, implying over 40% earnings growth as management targets meaningful margin recovery.